A prospective ascertainment of cancer incidence in sub-Saharan Africa: The case of Kaposi sarcoma

Aggrey Semeere, Megan Wenger, Naftali Busakhala, Nathan Buziba, Mwebesa Bwana, Winnie Muyindike, Erin Amerson, Toby Maurer, Timothy Mccalmont, Philip Leboit, Beverly Musick, Constantin Yiannoutsos, Robert Lukande, Barbara Castelnuovo, Miriam Laker-Oketta, Andrew Kambugu, David Glidden, Kara Wools-Kaloustian, Jeffrey Martin

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

In resource-limited areas, such as sub-Saharan Africa, problems in accurate cancer case ascertainment and enumeration of the at-risk population make it difficult to estimate cancer incidence. We took advantage of a large well-enumerated healthcare system to estimate the incidence of Kaposi sarcoma (KS), a cancer which has become prominent in the HIV era and whose incidence may be changing with the rollout of antiretroviral therapy (ART). To achieve this, we evaluated HIV-infected adults receiving care between 2007 and 2012 at any of three medical centers in Kenya and Uganda that participate in the East Africa International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium. Through IeDEA, clinicians received training in KS recognition and biopsy equipment. We found that the overall prevalence of KS among 102,945 HIV-infected adults upon clinic enrollment was 1.4%; it declined over time at the largest site. Among 140,552 patients followed for 319,632 person-years, the age-standardized incidence rate was 334/100,000 person-years (95% CI: 314-354/100,000 person-years). Incidence decreased over time and was lower in women, persons on ART, and those with higher CD4 counts. The incidence rate among patients on ART with a CD4 count >350 cells/mm3 was 32/100,000 person-years (95% CI: 14-70/100,000 person-years). Despite reductions over time coincident with the expansion of ART, KS incidence among HIV-infected adults in East Africa equals or exceeds the most common cancers in resource-replete settings. In resource-limited settings, strategic efforts to improve cancer diagnosis in combination with already well-enumerated at-risk denominators can make healthcare systems attractive platforms for estimating cancer incidence.

Original languageEnglish (US)
Pages (from-to)914-928
Number of pages15
JournalCancer Medicine
Volume5
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Africa South of the Sahara
Kaposi's Sarcoma
Incidence
Neoplasms
HIV
Eastern Africa
CD4 Lymphocyte Count
Acquired Immunodeficiency Syndrome
Databases
Delivery of Health Care
Uganda
Kenya
Therapeutics
Biopsy
Equipment and Supplies

Keywords

  • Africa
  • Antiretroviral therapy
  • HIV/AIDS
  • Incidence
  • Kaposi sarcoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Semeere, A., Wenger, M., Busakhala, N., Buziba, N., Bwana, M., Muyindike, W., ... Martin, J. (2016). A prospective ascertainment of cancer incidence in sub-Saharan Africa: The case of Kaposi sarcoma. Cancer Medicine, 5(5), 914-928. https://doi.org/10.1002/cam4.618

A prospective ascertainment of cancer incidence in sub-Saharan Africa : The case of Kaposi sarcoma. / Semeere, Aggrey; Wenger, Megan; Busakhala, Naftali; Buziba, Nathan; Bwana, Mwebesa; Muyindike, Winnie; Amerson, Erin; Maurer, Toby; Mccalmont, Timothy; Leboit, Philip; Musick, Beverly; Yiannoutsos, Constantin; Lukande, Robert; Castelnuovo, Barbara; Laker-Oketta, Miriam; Kambugu, Andrew; Glidden, David; Wools-Kaloustian, Kara; Martin, Jeffrey.

In: Cancer Medicine, Vol. 5, No. 5, 01.05.2016, p. 914-928.

Research output: Contribution to journalArticle

Semeere, A, Wenger, M, Busakhala, N, Buziba, N, Bwana, M, Muyindike, W, Amerson, E, Maurer, T, Mccalmont, T, Leboit, P, Musick, B, Yiannoutsos, C, Lukande, R, Castelnuovo, B, Laker-Oketta, M, Kambugu, A, Glidden, D, Wools-Kaloustian, K & Martin, J 2016, 'A prospective ascertainment of cancer incidence in sub-Saharan Africa: The case of Kaposi sarcoma', Cancer Medicine, vol. 5, no. 5, pp. 914-928. https://doi.org/10.1002/cam4.618
Semeere A, Wenger M, Busakhala N, Buziba N, Bwana M, Muyindike W et al. A prospective ascertainment of cancer incidence in sub-Saharan Africa: The case of Kaposi sarcoma. Cancer Medicine. 2016 May 1;5(5):914-928. https://doi.org/10.1002/cam4.618
Semeere, Aggrey ; Wenger, Megan ; Busakhala, Naftali ; Buziba, Nathan ; Bwana, Mwebesa ; Muyindike, Winnie ; Amerson, Erin ; Maurer, Toby ; Mccalmont, Timothy ; Leboit, Philip ; Musick, Beverly ; Yiannoutsos, Constantin ; Lukande, Robert ; Castelnuovo, Barbara ; Laker-Oketta, Miriam ; Kambugu, Andrew ; Glidden, David ; Wools-Kaloustian, Kara ; Martin, Jeffrey. / A prospective ascertainment of cancer incidence in sub-Saharan Africa : The case of Kaposi sarcoma. In: Cancer Medicine. 2016 ; Vol. 5, No. 5. pp. 914-928.
@article{63ef6b64c37749d7bba3eefeb24091ad,
title = "A prospective ascertainment of cancer incidence in sub-Saharan Africa: The case of Kaposi sarcoma",
abstract = "In resource-limited areas, such as sub-Saharan Africa, problems in accurate cancer case ascertainment and enumeration of the at-risk population make it difficult to estimate cancer incidence. We took advantage of a large well-enumerated healthcare system to estimate the incidence of Kaposi sarcoma (KS), a cancer which has become prominent in the HIV era and whose incidence may be changing with the rollout of antiretroviral therapy (ART). To achieve this, we evaluated HIV-infected adults receiving care between 2007 and 2012 at any of three medical centers in Kenya and Uganda that participate in the East Africa International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium. Through IeDEA, clinicians received training in KS recognition and biopsy equipment. We found that the overall prevalence of KS among 102,945 HIV-infected adults upon clinic enrollment was 1.4{\%}; it declined over time at the largest site. Among 140,552 patients followed for 319,632 person-years, the age-standardized incidence rate was 334/100,000 person-years (95{\%} CI: 314-354/100,000 person-years). Incidence decreased over time and was lower in women, persons on ART, and those with higher CD4 counts. The incidence rate among patients on ART with a CD4 count >350 cells/mm3 was 32/100,000 person-years (95{\%} CI: 14-70/100,000 person-years). Despite reductions over time coincident with the expansion of ART, KS incidence among HIV-infected adults in East Africa equals or exceeds the most common cancers in resource-replete settings. In resource-limited settings, strategic efforts to improve cancer diagnosis in combination with already well-enumerated at-risk denominators can make healthcare systems attractive platforms for estimating cancer incidence.",
keywords = "Africa, Antiretroviral therapy, HIV/AIDS, Incidence, Kaposi sarcoma",
author = "Aggrey Semeere and Megan Wenger and Naftali Busakhala and Nathan Buziba and Mwebesa Bwana and Winnie Muyindike and Erin Amerson and Toby Maurer and Timothy Mccalmont and Philip Leboit and Beverly Musick and Constantin Yiannoutsos and Robert Lukande and Barbara Castelnuovo and Miriam Laker-Oketta and Andrew Kambugu and David Glidden and Kara Wools-Kaloustian and Jeffrey Martin",
year = "2016",
month = "5",
day = "1",
doi = "10.1002/cam4.618",
language = "English (US)",
volume = "5",
pages = "914--928",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - A prospective ascertainment of cancer incidence in sub-Saharan Africa

T2 - The case of Kaposi sarcoma

AU - Semeere, Aggrey

AU - Wenger, Megan

AU - Busakhala, Naftali

AU - Buziba, Nathan

AU - Bwana, Mwebesa

AU - Muyindike, Winnie

AU - Amerson, Erin

AU - Maurer, Toby

AU - Mccalmont, Timothy

AU - Leboit, Philip

AU - Musick, Beverly

AU - Yiannoutsos, Constantin

AU - Lukande, Robert

AU - Castelnuovo, Barbara

AU - Laker-Oketta, Miriam

AU - Kambugu, Andrew

AU - Glidden, David

AU - Wools-Kaloustian, Kara

AU - Martin, Jeffrey

PY - 2016/5/1

Y1 - 2016/5/1

N2 - In resource-limited areas, such as sub-Saharan Africa, problems in accurate cancer case ascertainment and enumeration of the at-risk population make it difficult to estimate cancer incidence. We took advantage of a large well-enumerated healthcare system to estimate the incidence of Kaposi sarcoma (KS), a cancer which has become prominent in the HIV era and whose incidence may be changing with the rollout of antiretroviral therapy (ART). To achieve this, we evaluated HIV-infected adults receiving care between 2007 and 2012 at any of three medical centers in Kenya and Uganda that participate in the East Africa International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium. Through IeDEA, clinicians received training in KS recognition and biopsy equipment. We found that the overall prevalence of KS among 102,945 HIV-infected adults upon clinic enrollment was 1.4%; it declined over time at the largest site. Among 140,552 patients followed for 319,632 person-years, the age-standardized incidence rate was 334/100,000 person-years (95% CI: 314-354/100,000 person-years). Incidence decreased over time and was lower in women, persons on ART, and those with higher CD4 counts. The incidence rate among patients on ART with a CD4 count >350 cells/mm3 was 32/100,000 person-years (95% CI: 14-70/100,000 person-years). Despite reductions over time coincident with the expansion of ART, KS incidence among HIV-infected adults in East Africa equals or exceeds the most common cancers in resource-replete settings. In resource-limited settings, strategic efforts to improve cancer diagnosis in combination with already well-enumerated at-risk denominators can make healthcare systems attractive platforms for estimating cancer incidence.

AB - In resource-limited areas, such as sub-Saharan Africa, problems in accurate cancer case ascertainment and enumeration of the at-risk population make it difficult to estimate cancer incidence. We took advantage of a large well-enumerated healthcare system to estimate the incidence of Kaposi sarcoma (KS), a cancer which has become prominent in the HIV era and whose incidence may be changing with the rollout of antiretroviral therapy (ART). To achieve this, we evaluated HIV-infected adults receiving care between 2007 and 2012 at any of three medical centers in Kenya and Uganda that participate in the East Africa International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium. Through IeDEA, clinicians received training in KS recognition and biopsy equipment. We found that the overall prevalence of KS among 102,945 HIV-infected adults upon clinic enrollment was 1.4%; it declined over time at the largest site. Among 140,552 patients followed for 319,632 person-years, the age-standardized incidence rate was 334/100,000 person-years (95% CI: 314-354/100,000 person-years). Incidence decreased over time and was lower in women, persons on ART, and those with higher CD4 counts. The incidence rate among patients on ART with a CD4 count >350 cells/mm3 was 32/100,000 person-years (95% CI: 14-70/100,000 person-years). Despite reductions over time coincident with the expansion of ART, KS incidence among HIV-infected adults in East Africa equals or exceeds the most common cancers in resource-replete settings. In resource-limited settings, strategic efforts to improve cancer diagnosis in combination with already well-enumerated at-risk denominators can make healthcare systems attractive platforms for estimating cancer incidence.

KW - Africa

KW - Antiretroviral therapy

KW - HIV/AIDS

KW - Incidence

KW - Kaposi sarcoma

UR - http://www.scopus.com/inward/record.url?scp=85006210836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006210836&partnerID=8YFLogxK

U2 - 10.1002/cam4.618

DO - 10.1002/cam4.618

M3 - Article

C2 - 26823008

AN - SCOPUS:85006210836

VL - 5

SP - 914

EP - 928

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 5

ER -